Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stewart Gaede

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Cancers|June 26, 2026
Determining Optimal Fractionation of Neoadjuvant Radiation in Low-Risk, Early-Stage Breast Cancer-Randomized SIGNAL Clinical TrialMelanie Spears, Michael Lock, Brian Yaremko, et al.
Thoracic Cancer|May 25, 2022
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trialRichard A Malthaner, Edward Yu, Michael Sanatani, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 2022
Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized TrialMatthew Van Oirschot, Alanah Bergman, Wilko F A R Verbakel, et al.
Radiation Oncology (London, England)|January 29, 2017
Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)David A Palma, Timothy K Nguyen, Keith Kwan, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2019
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized TrialRobert Olson, Suresh Senan, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics|October 3, 2024
Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: Long-Term Clinical OutcomesVivian S Tan, Rohann J M Correa, Timothy K Nguyen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized TrialX Melody Qu, Yujie Chen, Gregory S Zaric, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2022
Functional Lung Avoidance for Individualized Radiation Therapy: Results of a Double-Masked, Randomized Controlled TrialBrian P Yaremko, Dante P I Capaldi, Khadija Sheikh, et al.
Lancet (London, England)|April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialDavid A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2022
Planning Trade-offs for SABR in Patients With 4 to 10 Metastases: A Substudy of the SABR-COMET-10 Randomized TrialSamaher Ashram, Houda Bahig, Aisling Barry, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Cancers|June 26, 2026
Determining Optimal Fractionation of Neoadjuvant Radiation in Low-Risk, Early-Stage Breast Cancer-Randomized SIGNAL Clinical TrialMelanie Spears, Michael Lock, Brian Yaremko, et al.
Thoracic Cancer|May 25, 2022
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trialRichard A Malthaner, Edward Yu, Michael Sanatani, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 2022
Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized TrialMatthew Van Oirschot, Alanah Bergman, Wilko F A R Verbakel, et al.
Radiation Oncology (London, England)|January 29, 2017
Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)David A Palma, Timothy K Nguyen, Keith Kwan, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2019
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized TrialRobert Olson, Suresh Senan, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics|October 3, 2024
Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: Long-Term Clinical OutcomesVivian S Tan, Rohann J M Correa, Timothy K Nguyen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized TrialX Melody Qu, Yujie Chen, Gregory S Zaric, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2022
Functional Lung Avoidance for Individualized Radiation Therapy: Results of a Double-Masked, Randomized Controlled TrialBrian P Yaremko, Dante P I Capaldi, Khadija Sheikh, et al.
Lancet (London, England)|April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialDavid A Palma, Robert Olson, Stephen Harrow, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2022
Planning Trade-offs for SABR in Patients With 4 to 10 Metastases: A Substudy of the SABR-COMET-10 Randomized TrialSamaher Ashram, Houda Bahig, Aisling Barry, et al.
Pageof 8